1/9 Economic headwinds in China are exposing more and more companies to value erosion situations. In this thread, we share our experience of how best to understand and lead the turnaround process in China.
#InterChina#chinabusiness#turnaround
InterChina's Barry Chen interviewed on the Deal Cast pocast: Chinese M&A activity in 2023, inbound and outbound, strategic and PE https://t.co/pqWhAJQZIP
9/9 Read more "Responding To Challenges In The Chinese Healthcare Market" ➡️
Part I: Volume Based Procurement
https://t.co/4wp68x5F8H
Part II: Local Product Procurement
https://t.co/Q8g9DDmEqk
Part III: Medical Insurance
https://t.co/tLdi1leL77
1/9
China's healthcare sector was once extremely attractive to multinationals selling pharmaceuticals and medical devices. But those days have gone as China sets out on a long-term plan to tackle spiralling healthcare costs.
#InterChina#chinabusiness#chinahealthcare
8/9
Multinational suppliers should increasingly pursue locally sourced innovation and product pipeline expansion to override these new challenges. And with China abuzz with innovation, it could be that the M&A route is the best way for many multinationals to achieve these goals.
6/6
As the industry’s cards are reshuffled there is a unique window of opportunity – perhaps only three to five years – for multinationals to get on board China’s great hydrogen opportunity.
1/6
Over the last decade China has built a strong presence in green markets. Today, all the signs point to a similar revolution in its green hydrogen industry.
Read: https://t.co/gufacFawy7
#chinabusiness#greenenergy#hydrogen
5/6
China still needs extensive foreign technology and investment to grow its FCEV market, especially in areas such as proton exchange membranes which are a crucial component in a hydrogen cell system.